Journal
IMMUNOTHERAPY
Volume 11, Issue 13, Pages 1095-1105Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2019-0047
Keywords
allergic rhinitis; miR-146a; NF-kappa B; TLR4; TRAF6
Categories
Funding
- Jilin Electric Research Funding
Ask authors/readers for more resources
Aim: This study aims to investigate whether microRNA (miR)-146a exerts therapeutic potential to allergic rhinitis (AR). Methods: Female BALB/cmice were randomly divided into the AR and miR-146a groups. miR-146a was administered into the nostril before ovalbumin (OVA) challenge daily on days 21-28. Results: The expression level of miR-146a in AR nasal mucosa was significantly decreased. miR-146a mimic markedly attenuated sneezing and nasal rubbing events, decreased the levels of ovalbumin-specific IgE as well as mastocyte- and basophil-related inflammatory cytokines, reduced inflammatory cells, affected the T-helper 2-released cytokines. Furthermore, miR-146a mimic inhibited the expressions of proteins relevant to Toll-like receptor 4 (TLR4)/TRAF6/NF-kappa B signaling pathway. Conclusion: The anti-inflammatory effects of miR-146a on AR might exert through the inhibition of the toll-like receptor 4 (TLR4)/TRAF6/NF-kappa B signaling pathway to some extent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available